Business Context and Reporting Period
This Form 8-K was filed by Novus Therapeutics, Inc. on July 10, 2017. The report discloses the appointment of a new Senior Vice President of Finance and Administration and the departure of the previous Chief Financial and Compliance Officer. Note: The request metadata references "Eledon Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as Novus Therapeutics, Inc.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Appointment: Jon Kuwahara was appointed Senior Vice President of Finance and Administration, replacing Christine G. Ocampo as the principal accounting and financial officer.
- Executive Departure: Christine G. Ocampo, who served as Chief Financial and Compliance Officer since May 2017, will transition to a consultant role through 2018.
- Compensation Structure: Mr. Kuwahara's annual base salary is set at $275,000 with a target bonus of 30% of base salary.
- Equity Grant: Mr. Kuwahara received an inducement option to purchase 35,000 shares of common stock. The option vests 25% on the first anniversary and the remainder ratably over the subsequent three years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. It notes that the equity option was granted outside of shareholder-approved plans but is governed by the terms of the 2014 Stock Incentive Plan. No unusual items were reported.
Investor Verification Checklist
- Verify the correct registrant name (Novus Therapeutics, Inc.) versus the metadata reference (Eledon Pharmaceuticals, Inc.).
- Confirm the vesting schedule and exercise price of the 35,000-share inducement option granted to Jon Kuwahara.
- Review the terms of the consulting agreement with Christine G. Ocampo to understand ongoing financial reporting responsibilities.
- Check subsequent filings for the impact of this leadership change on the company's financial reporting and internal controls.